Adaptimmune Therapeutics Plc RSI
Was ist das RSI von Adaptimmune Therapeutics Plc?
RSI von Adaptimmune Therapeutics Plc ist 44.50
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adaptimmune Therapeutics Plc
Was macht Adaptimmune Therapeutics Plc?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Unternehmen mit rsi ähnlich Adaptimmune Therapeutics Plc
- Rada Electronic Industries hat RSI von 44.48
- Alerus hat RSI von 44.49
- First Bancshares Inc Miss hat RSI von 44.49
- Jerrick Media hat RSI von 44.49
- Peeks Social hat RSI von 44.49
- West Vault Mining hat RSI von 44.49
- Adaptimmune Therapeutics Plc hat RSI von 44.50
- MKS Instruments hat RSI von 44.51
- RedFlow hat RSI von 44.51
- Shenguan () hat RSI von 44.51
- Invesco Mortgage Capital Inc hat RSI von 44.51
- Topaz hat RSI von 44.51
- Pure Gold Mining hat RSI von 44.51